Merck & Co., Inc.
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 13, 2025), Merck & Co., Inc. reported 13 stock positions worth $215.6 million. Its top holding was Personalis (PSNL) at 42.7% of the portfolio, followed by Moderna (MRNA, 29.5%) and Kymera Therapeutics (KYMR, 15.6%). Compared with Q1 2025, it opened 1 new position. The biggest buy was a new position in Tuhura Biosciences (HURA).
- Most Recent 13F
- Q2 2026
- Location
- RAHWAY, NJ
- CIK
- 0000310158
- Portfolio Value
- $215.6M (Q2 2025)
- SEC Filing
- 0001691304-25-000005 ↗ filed Aug 13, 2025
Holdings Value
Holdings 13 stocks · $215.6M
| PSNL Personalis Inc. | 42.73% | 14,044,943 | $92.1M | No change |
| MRNA Moderna Inc. | 29.54% | 2,308,190 | $63.7M | No change |
| KYMR Kymera Therapeutics Inc. | 15.63% | 772,165 | $33.7M | No change |
| ENTRADA THERAPEUTICS INC | 5.42% | 1,739,768 | $11.7M | No change |
| ALEC Alector Inc. | 2.30% | 3,545,719 | $5.0M | No change |
| EVAX Evaxion Biotech A/S | 1.38% | 1,214,126 | $3.0M | No change |
| STRO Sutro Biopharma Inc. Com SHS | 0.90% | 2,723,509 | $1.9M | No change |
| LVTX Lava Therapeutics NV | 0.70% | 1,149,345 | $1.5M | No change |
| VRDN Viridian Therapeutics Inc. | 0.61% | 93,414 | $1.3M | No change |
| XLO Xilio Therapeutics Inc. | 0.47% | 1,483,758 | $1.0M | No change |
| CARM Carisma Therapeutics Inc. | 0.27% | 1,473,240 | $577K | No change |
| NEUP Neuphoria Therapeutics Inc. | 0.03% | 10,027 | $71K | No change |
| HURA Tuhura Biosciences Inc. | 0.01% | 13,950 | $31K | New |
Portfolio Sells Q1 2025 → Q2 2025
| None this quarter. | |||
Portfolio Buys Q1 2025 → Q2 2025
| HURA Tuhura Biosciences Inc. | New | 0.01% | +0.01 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $526.4M | PSNL, MRNA, KYMR, AKTS, EIKN |
| Q1 2026 | 14 | $349.4M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, EIKN |
| Q4 2025 | 12 | $276.3M | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, EVAX |
| Q3 2025 | 13 | $228.0M | PSNL, MRNA, KYMR, ALEC, ENTRADA THERAPEUTICS INC |
| Q2 2025 | 13 | $215.6M | PSNL, MRNA, KYMR, ENTRADA THERAPEUTICS INC, ALEC |
| Q1 2025 | 12 | $164.3M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC |
| Q4 2024 | 13 | $258.0M | MRNA, PSNL, KYMR, ENTRADA THERAPEUTICS INC, ALEC |